Skip to main content

Table 2 HSDS Change from Baseline Stratified by Age at Treatment Start and by Gender

From: Effect of 4 years of growth hormone therapy in children with Noonan syndrome in the American Norditropin Studies: Web-Enabled Research (ANSWER) Program® registry

 

Boys

Girls

<11 years

≥11 years

 

<10 years

≥10 years

 

N

Mean (SD)

N

Mean (SD)

P value

N

Mean (SD)

N

Mean (SD)

P value

Y1

32

0.53 (0.36)

22

0.24 (0.34)

0.0046

12

0.42 (0.51)

10

0.29 (0.38)

0.5159

Y2

25

0.94 (0.65)

13

0.47 (0.50)

0.0284

6

0.77 (0.55)

5

0.49 (0.67)

0.4726

Y3

16

0.92 (0.65)

10

1.01 (0.65)

0.7168

2

1.24 (0.33)

3

1.24 (0.45)

0.9968

Y4

6

1.15 (0.93)

8

0.90 (0.88)

0.6082

2

1.34 (0.78)

1

1.52 (—)

—

  1. P values are for comparisons between age groups for each year.
  2. HSDS, height standard deviation score; SD, standard deviation; Y1, year 1; Y2, year 2; Y3, year 3; Y4, year 4.
Back to article page

International Journal of Pediatric Endocrinology

ISSN: 1687-9856

Contact us